MLLT1 and acute lymphoblastic leukemia: We subsequently examined the efficacy of the CBL0137 and panobinostat combination in a highly aggressive human PDX model of infant KMT2A-r ALL (MLL-6), which harbors a KMT2A:MLLT1 rearrangement (25, 26).